Abstract
Objective: The pharmacokinetics and pharmacodynamics of buffered sublingual captopril were assessed in patients with congestive heart failure (CHF).
Methods: The study was carried out in a randomised single-blind cross-over fashion (n=6, 4 males and 2 females) and involved two study days, at least 7 days apart. Baseline measurements were carried out for plasma renin activity (PRA), blood pressure (B.P.) and heart rate (H.R.). Captopril (12.5 mg) was administered sublingually with dibasic potassium phosphate which maintained salivary pH at 7, or perorally with 100 ml of water. Further B.P., H.R. measurements and venous blood samples were taken over a 3 hour period post-drug administration. Blood samples were analysed for captopril and PRA levels.
Results: tmax after buffered sublingual administration of captopril, which ranged from 40–60 min (median=40 min), was significantly shorter than after peroral administration (range 60–120 min, median=90 min). Cmax was slightly greater after buffered sublingual than after peroral administration with mean values of 108.2 vs. 94.0 ng·ml−1. AUC values were similar after both routes of administration. Systolic and diastolic B.P. vs. time profiles for each administration method were significantly different i.e. sublingual administration produced an earlier reduction in B.P., however, HR did not differ significantly between the two routes.
Conclusion: The data indicate that this novel administration method of captopril leads to an increased rate, but an unchanged extent of captopril absorption, suggesting a modest therapeutic advantage with the use of buffered sublingual captopril if a rapid reduction in blood pressure is required.
Similar content being viewed by others
References
Crozier I, Ikram H (1992) Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure. Drugs 43:637–650
Chow M (1993) Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin converting enzyme inhibitors. Pharmacotherapy 13:82S-87S
Cody RJ, Schaer GL and Covit AB, Pondolfno K, Williams G (1992) Captopril kinetics in chronic congestive heart failure. Clin Pharmacol Ther 32:721–726
Duchin KL, McKinstry DN, Cohen AI, Migdalof BH (1988) Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet 14:241–259
Brogden RN, Todd PA, Sorkin EM (1988) Captopril: An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 36:540–600
Ceyhan B, Karaaslan Y, Caymaz O, Oto A, Oram E, Oram A, Ugurlu S (1990) Comparison of sublingual captopril and sublingual nifedipine in hypertensive emergencies. Jap J Pharmacol 52:189–193
Longhini C, Ansani L, Musacci G, Mele D, Vaccari M, Baracca E, Sgobino P (1990) The effect of captopril on peripheral haemodynamics in patients with essential hypertension: comparison between oral and sublingual administration. Cardiovasc Drugs Ther 4:751–754
Angeli P, Chiesa M, Caregaro L, Merkel C, Sacerdoti D, Rondana M, Gatta A (1991) Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. Arch Intern Med 151:678–682
Wu SG, Lin SL, Shiao WY, Huang HW, Lin CF, Yang YH (1993) Comparison of sublingual captopril, nifedipine and prazosin in hypertensive emergencies during hemodialysis. Nephron 65:284–287
Haude M, Steffen W, Erbel R, Meyer J (1990) Sublingual administration of captopril versus nitroglycerin in patients with severe congestive heart failure. Int J Cardiol 27:351–359
Al-Furaih TA, McElnay JC, Elborn JS, Rusk R, Scott MG, McMahon J, Nicholls DP (1991) Sublingual captopril-a pharmacokinetic and pharmacodynamic evaluation. Eur J Clin Pharmacol 40:393–398
McElnay JC, Al-Furaih TA, Hughes CM, Elborn JS (1995) The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol 48:373–379
Pereira CM, Tam YK (1988) Simplified determination of captopril in plasma by high performance liquid chromatography. J Chromatogr 425:208–213
Harris D, Robinson JR (1992) Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 81:1–10
Creasy WA, Funke PT, McKinstry DN, Sugerman AA (1986) Pharmacokinetics of captopril in elderly healthy male volunteers. J Clin Pharmacol 26:264–268
Martinez Amenos A, Carratala J, Pinto X, Santalo M, Tamayo C, Pujol M (1987) Hypertensive crisis: a comparative study of oral captopril, sublingual captopril and sublingual nifedipine. Med Clin 89:59–61
Dessi-Fulgheri P, Bandiera F, Rubattu S, Cocco F, Madeddu P, Oppes M, Tonol GC, Glorioso N, Rappeli A (1987) Comparison of sublingual and oral captopril in hypertension. Clin Expt Theory Prac 9:593–597
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McElnay, J.C., Al-Furaih, T.A., Hughes, C.M. et al. A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. Eur J Clin Pharmacol 49, 471–476 (1996). https://doi.org/10.1007/BF00195933
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00195933